107 related articles for article (PubMed ID: 1693537)
1. Increased numbers of CD8+CD11+, CD8+CD11- and CD8+Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Yabe H; Yabe M; Kato S; Kimura M; Iwaki K
Bone Marrow Transplant; 1990 May; 5(5):295-300. PubMed ID: 1693537
[TBL] [Abstract][Full Text] [Related]
2. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
[TBL] [Abstract][Full Text] [Related]
3. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
[TBL] [Abstract][Full Text] [Related]
4. [Flow cytometric analysis of T lymphocyte subsets after human bone marrow transplantation using monoclonal antibodies and dual immunofluorescence].
Matsue K; Yasue S; Iwabuchi K; Ohtsuka M; Ueda M; Kondo K; Shiobara S; Mori T; Matsuda T; Harada M
Nihon Ketsueki Gakkai Zasshi; 1989 May; 52(3):659-64. PubMed ID: 2694718
[TBL] [Abstract][Full Text] [Related]
5. Marked increase of CD57+CD16- cells in long-term survivors of graft-versus-host disease after allogeneic bone marrow transplantation.
Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
Jpn J Clin Oncol; 1992 Aug; 22(4):238-43. PubMed ID: 1359173
[TBL] [Abstract][Full Text] [Related]
6. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation.
Charmot D; Ragueneau M; Olive D; Maraninchi D; Mawas C
Bone Marrow Transplant; 1987 Aug; 2(2):183-94. PubMed ID: 2901879
[TBL] [Abstract][Full Text] [Related]
7. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
8. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory cells in graft-versus-host disease on the rectum: immunopathologic analysis.
Weisdorf SA; Roy J; Snover D; Platt JL; Weisdorf DJ
Bone Marrow Transplant; 1991 Apr; 7(4):297-301. PubMed ID: 2070136
[TBL] [Abstract][Full Text] [Related]
10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
11. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
[TBL] [Abstract][Full Text] [Related]
12. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
15. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry.
Atkinson K
Bone Marrow Transplant; 1986 Dec; 1(2):121-32. PubMed ID: 2971408
[TBL] [Abstract][Full Text] [Related]
16. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.
Paz Morante M; Briones J; Canto E; Sabzevari H; Martino R; Sierra J; Rodriguez-Sanchez JL; Vidal S
Clin Exp Immunol; 2006 Jul; 145(1):36-43. PubMed ID: 16792671
[TBL] [Abstract][Full Text] [Related]
17. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation.
Rojas B; Cuhna R; Zafirakis P; Ramirez JM; Lizan-garciía M; Zhao T; Foster CS
Exp Eye Res; 2005 Sep; 81(3):313-25. PubMed ID: 16129099
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
19. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
20. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
